Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.
Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of $17 million for twelve months ending June 2020. Alembic Pharmaceuticals has a cumulative total of 133 ANDA (115final approvals and 18tentaive approval) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
